Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Lon Smith"'
Autor:
Alyssa Simonson, Johnnie Flores, Ebony Anderson, Crystal Moreno, George Plasko, Kyriakos P. Papadopoulos, Amita Patnaik, Drew Rasco, Gladys Rodriguez, Amy Lang, Muralidhar Beeram, Luis Rodriguez, Ronald Drengler, Steven Abbate, Hanni Salih, Lon Smith, Maryam Elmi, Brittany DeBerry, Arthur Rosenthal, Tatiana Hernandez, Nehal Lakhani, Manish Sharma, Michael Wick
Publikováno v:
Cancer Research. 83:P3-08
Background: Sacituzumab govitecan (SG) is an antibody-drug conjugate targeting Trop2 with an SN-38 payload recently approved for pretreated patients with locally advanced or metastatic triple-negative breast cancer (TNBC). The XenoSTART Patient-Deriv
Autor:
Anthony W. Tolcher, Robert Iannone, Manfred Lehnert, Omar Laterza, Dianna Wu, Jennifer H. Yearley, Robert H. Pierce, Xiaoyun Nicole Li, Jill A. Lindia, Adil Daud, Liliana Delgado, Kevin Gergich, Guillermo Espino, Lon Smith, Cong Chen, Ronald Drengler, Muralidhar Beeram, Jeroen Elassaiss-Schaap, Kyriakos P. Papadopoulos, Drew Rasco, S. Peter Kang, Amita Patnaik
Supplementary Tables S1-2, Figure 1. Supplementary Table S1. Matrix view of Part A-2 dose titration and PK sampling scheme. Supplementary Table S2. Efficacy outcomes by investigator review per RECIST v1.1. Supplementary Figure 1. Seventeen patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1ae6624676b8c9357bd38e7a90e5906
https://doi.org/10.1158/1078-0432.22458957.v1
https://doi.org/10.1158/1078-0432.22458957.v1
Autor:
Anthony W. Tolcher, Robert Iannone, Manfred Lehnert, Omar Laterza, Dianna Wu, Jennifer H. Yearley, Robert H. Pierce, Xiaoyun Nicole Li, Jill A. Lindia, Adil Daud, Liliana Delgado, Kevin Gergich, Guillermo Espino, Lon Smith, Cong Chen, Ronald Drengler, Muralidhar Beeram, Jeroen Elassaiss-Schaap, Kyriakos P. Papadopoulos, Drew Rasco, S. Peter Kang, Amita Patnaik
Figure S1. Seventeen patients were tested with IFN-γ ELISPOT assay.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16e220a1eccfcdb6f3a462617ffb5cdd
https://doi.org/10.1158/1078-0432.22458960
https://doi.org/10.1158/1078-0432.22458960
Autor:
Anthony W. Tolcher, Robert Iannone, Manfred Lehnert, Omar Laterza, Dianna Wu, Jennifer H. Yearley, Robert H. Pierce, Xiaoyun Nicole Li, Jill A. Lindia, Adil Daud, Liliana Delgado, Kevin Gergich, Guillermo Espino, Lon Smith, Cong Chen, Ronald Drengler, Muralidhar Beeram, Jeroen Elassaiss-Schaap, Kyriakos P. Papadopoulos, Drew Rasco, S. Peter Kang, Amita Patnaik
Purpose: This phase I study evaluated the safety, maximum tolerated dose, antitumor activity, and pharmacokinetics and pharmacodynamics of pembrolizumab in patients with advanced solid tumors.Experimental Design: In a 3 + 3 dose escalation study, 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d2b3af4d7d6a9200060a71f6cc4555e
https://doi.org/10.1158/1078-0432.c.6524094
https://doi.org/10.1158/1078-0432.c.6524094
Autor:
Amita Patnaik, Erika Hamilton, Yan Xing, Drew W. Rasco, Lon Smith, Ya-Li Lee, Steven Fang, Jiao Wei, Ai-Min Hui
Publikováno v:
Cancers; Volume 14; Issue 20; Pages: 4996
A phase I study evaluated the safety, tolerability, and maximum-tolerated dose (MTD)/recommended phase II dose (RP2D) of FCN-437c, a novel, orally available cyclin-dependent kinase inhibitor (CDK4/6i), in participants with advanced/metastatic solid t
Autor:
Alyssa Simonson, Johnnie Flores, Lizette Firova, Christian Hernandez, Morgan Harris, Kyriakos Papadopoulos, Drew Rasco, Amita Patnaik, Allan White, Lon Smith, Ronald Drengler, Amy Lang, Murali Beeram, Michael J. Wick
Publikováno v:
Cancer Research. 82:1092-1092
Background: First-line treatment for some cancer types includes platinum-based therapy. While the rate of initial response to treatment is high, most patients develop platinum-resistant disease. Current salvage therapy provides benefit to some patien
Autor:
Johnnie Flores, Alyssa Simonson, Peter Forofontov, Anna Stackpole, Drew Rasco, Amita Patnaik, Kyriakos Papadopoulos, Teresa DesRochers, Natalie Williams, Ronald Drengler, Lon Smith, Michael J. Wick
Publikováno v:
Cancer Research. 82:412-412
Background: We previously reported (RAS AACR 2022) a preclinical screen testing KRASG12C-inhibitors (KRASG12C-i) in 13 colorectal and 13 lung KRASG12C XPDX models; all tested models were from patients naïve to KRASG12C-i. To better understand mechan
Autor:
Alyssa Simonson, Peter Forofontov, Johnnie R Flores, Kimberly Hernandez, April Cabang, Amy Lang, Gladys Rodriguez, Kyriakos Papadopoulos, Murali Beeram, Arthur Rosenthal, Brittany DeBerry, Lon Smith, Ronald Drengler, Amita Patnaik, Drew Rasco, Luis Rodriguez, Steven Abbate, Scott Ulmer, Michael Wick
Publikováno v:
Cancer Research. 82:P5-01
Background: 15-20% of metastatic breast cancers are characterized by overexpression or amplification of human epidermal growth factor receptor 2 (HER2). First-line treatment for HER2-positive metastatic breast cancer includes the anti-HER2 monoclonal
Autor:
April Cabang, Crystal Moreno, Johnnie R Flores, Jenna Boedeker, Alyssa Simonson, Jun Ma, Amy Lang, Gladys Rodriguez, Arthur Rosenthal, Kyriakos Papadopoulos, Amita Patnaik, Drew Rasco, Lon Smith, Murali Beeram, Ronald Drengler, Luis Rodriguez, Steven Abbate, Scott Ulmer, Michael J Wick
Publikováno v:
Cancer Research. 82:P5-01
Background: Fulvestrant is a selective estrogen receptor modulator (SERM) approved as a single agent for estrogen receptor positive, HER2 negative breast cancer patients at various stages of disease and in combination with CDK4/6 inhibitors following
Autor:
Lon Smith, Amita Patnaik, Charlene Mantia, Jou-Ku Chung, Beth Bowers, Daniel Morgensztern, Kerry White, Lauren C. Harshman, Aung Naing, Jonathan A. Hill, Gaia Sciaranghella, Benjamin H. Lee, Toni K. Choueiri, Nizar M. Tannir
Publikováno v:
Journal of Clinical Oncology. 39:2551-2551
2551 Background: IL-27 is an immunosuppressive cytokine, consisting of two subunits p28 and EBI3, that upregulates immune checkpoint receptors (eg, PD-L1, TIGIT) and downregulates proinflammatory cytokines such as IFNγ, TNFα, and IL-17. SRF388 is a